Reasons underlying non-adherence to and discontinuation of anticoagulation in secondary stroke prevention among patients with atrial fibrillation

European Neurology

Volumn 73, Issue 3-4, 2015, Pages 184-191

  Gumbinger, Christoph ^a   Holstein, Timo ^a   Stock, Christian ^a   Rizos, Timolaos ^a   Horstmann, Solveig ^a   Veltkamp, Roland ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Acute stroke; Adherence; Emergency room; Neurology; Oral anticoagulation; Treatment interruption

Indexed keywords

ANTICOAGULANT AGENT;

AGED; ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; DRUG WITHDRAWAL; EPISTAXIS; FALL RISK; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; GASTROINTESTINAL HEMORRHAGE; GENERAL PRACTITIONER; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NURSING HOME; OBSERVATIONAL STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); PRESCRIPTION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; STROKE PATIENT; TELEPHONE INTERVIEW; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT REFUSAL; TREATMENT WITHDRAWAL; CLINICAL PRACTICE; COMPLICATION; INTERNATIONAL NORMALIZED RATIO; MIDDLE AGED; PHYSICIAN; PROCEDURES; STATISTICS AND NUMERICAL DATA; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; COHORT STUDIES; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PHYSICIANS; PRACTICE PATTERNS, PHYSICIANS'; PROSPECTIVE STUDIES; RISK FACTORS; SECONDARY PREVENTION; STROKE;

EID: 84921896548     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000371574     Document Type: Article

References (30)

1. Aguilar MI, Hart R: Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Stroke 2008; 39: 1399-1400.
2. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Higashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijdicks EF: Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007; 38: 1655-1711.
3. Bauersachs RM, Schellong S, Haas S, Gogarten W, Riess H, Omran H: Überbrückung der oralen Antikoagulation bei interventionellen Eingriffen. Dtsch Arztebl 2007; 104: A-1237.
4. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery; Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, de Caterina R, de Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH: Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
5. Chiquette E, Amato MG, Bussey HI: Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998; 158: 1641-1647.
6. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
7. Heart and Stroke Statistical-2002 Update. Dallas, TX, American Heart Association, 2001. http://www.americanheart.org/statistics/ index.html.
8. Donzé J, Clair C, Hug B, Rodondi N, Waeber G, Cornuz J, Aujesky D: Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med 2012; 125: 773-778.
9. Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS, Kunz R: Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidencebased clinical practice guidelines. Chest 2012; 141(2 suppl):e326S-e350S.
10. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375.
11. Goldstein LB, Rothwell PM: Advances in primary prevention and health services delivery. Stroke 2009; 40:e295-e297.
12. Gorin L, Fauchier L, Nonin E, de Labriolle A, Haguenoer K, Cosnay P, Babuty D, Charbonnier B: Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1. Thromb Haemost 2010; 103: 833-840.
13. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25: 457-507.
14. Hart RG: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
15. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, Themeles E, Heidbuchel H, Avezum A, Reilly P, Connolly SJ, Yusuf S, Ezekowitz M: Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation 2012; 126: 343-348.
16. Lalouschek W, Lang W, Mullner M: Current strategies of secondary prevention after a cerebrovascular event: the Vienna stroke registry. Stroke 2001; 32: 2860-2866.
17. Mazzaglia G, Filippi A, Alacqua M, Cowell W, Shakespeare A, Mantovani LG, Bianchi C, Cricelli C: A national survey of the management of atrial fibrillation with antithrombotic drugs in Italian primary care. Thromb Haemost 2010; 103: 968-975.
18. McBride D, Bruggenjurgen B, Roll S, Willich SN: Anticoagulation treatment for the reduction of stroke in atrial fibrillation: a cohort study to examine the gap between guidelines and routine medical practice. J Thromb Thrombolysis 2007; 24: 65-72.
19. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY: Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010; 123: 638-645.e4.
20. Parker CS, Chen Z, Price M, Gross R, Metlay JP, Christie JD, Brensinger CM, Newcomb CW, Samaha FF, Kimmel SE: Adherence to warfarin assessed by electronic pill caps, clinician assessment, and patient reports: results from the IN-RANGE study. J Gen Intern Med 2007; 22: 1254-1259.
21. Pereira-Da-Silva T, Souto Moura T, Azevedo L, Sa Pereira M, Virella D, Alves M, Borges L: [Restraints to anticoagulation prescription in atrial fibrillation and attitude towards the new oral anticoagulants]. Acta Med Port 2013; 26: 127-132.
22. Pereira de Sousa L, Burba I, Ruperto C, Lattuada L, Barbone F, Di Chiara A: Vitamin K antagonists in patients with nonvalvular atrial fibrillation. J Cardiovasc Med 2013; 14: 534-540.
23. Pfeilschifter W, Luger S, Brunkhorst R, Lindhoff-Last E, Foerch C: The gap between trial data and clinical practice-an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation. Cerebrovasc Dis 2013; 36: 115-119.
24. Pisters R: A novel user-friendly score (HASBLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation. Chest 2010; 138: 1093-1100.
25. R Development Core Team (2013): R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project. org/.
26. Raunsø J, Selmer C, Olesen JB, Charlot MG, Olsen AM, Bretler D, Nielsen JD, Dominguez H, Gadsbøll N, Køber L, Gislason GH, Torp-Pedersen C, Hansen ML: Increased shortterm risk of thrombo-embolism or death after interruption of warfarin treatment in patients with atrial fibrillation. Eur Heart J 2012; 33: 1886-1892.
27. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993; 342: 1255-1262.
28. Touze E, Cambou JP, Ferrieres J, Vahanian A, Coppe G, Leizorovicz A, Jullien G, Guerillot M, Herrmann M, Mas J: Antithrombotic management after an ischemic stroke in French primary care practice: results from three pooled cross-sectional studies. Cerebrovasc Dis 2005; 20: 78-84.
29. Waldo AL, Becker RC, Tapson VF, Colgan KJ: Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol 2005; 46: 1729-1736.
30. Weimar C, Benemann J, Katsarava Z, Weber R, Diener H: Adherence and quality of oral anticoagulation in cerebrovascular disease patients with atrial fibrillation. Eur Neurol 2008; 60: 142-148.